Ruxolitinib, 98%, a potent and selective JAK1/2 inhibitor

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity

Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors

HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents

Synthesis and clinical application of small-molecule inhibitors of Janus kinase